BioLineRx is trading at $2.57, up +6.28%, with the catalyst uncertain. - No clear company-specific announcement was identified for September 23, 2026. - The annual shareholder meeting is scheduled for September 23, 2026, with votes on authorized capital and equity awards; no direct price impact was confirmed. - The broader market and biotech sector were lower, so neither clearly explains the move higher.